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Background: Survivin is known playing a role in drug resistance. However, its role in bortezomib-mediated
inhibition of growth and induction of apoptosis is unclear. There are conflicting reports for the effect of
bortezomib on survivin expression, which lacks of a plausible explanation. Methods: In this study, we tested cancer
cells with both p53 wild type and mutant/null background for the relationship of bortezomib resistance with
survivin expression and p53 status using MTT assay, flow cytometry, DNA fragmentation, caspase activation,
western blots and RNAi technology.
Results: We found that cancer cells with wild type p53 show a low level expression of survivin and are sensitive to
treatment with bortezomib, while cancer cells with a mutant or null p53 show a high level expression of survivin
and are resistant to bortezomib-mediated apoptosis induction. However, silencing of survivin expression utilizing
survivin mRNA-specific siRNA/shRNA in p53 mutant or null cells sensitized cancer cells to bortezomib mediated
apoptosis induction, suggesting a role for survivin in bortezomib resistance. We further noted that modulation of
survivin expression by bortezomib is dependent on p53 status but independent of cancer cell types. In cancer cells
with mutated p53 or p53 null, bortezomib appears to induce survivin expression, while in cancer cells with wild
type p53, bortezomib downregulates or shows no significant effect on survivin expression, which is dependent on
the drug concentration, cell line and exposure time.
Conclusions: Our findings, for the first time, unify the current inconsistent findings for bortezomib treatment and
survivin expression, and linked the effect of bortezomib on survivin expression, apoptosis induction and
bortezomib resistance in the relationship with p53 status, which is independent of cancer cell types. Further
mechanistic studies along with this line may impact the optimal clinical application of bortezomib in solid cancer
therapeutics.
Background
Although bortezomib (PS-341) was largely applied to
treatment of hematopoieticm a l i g n a n c ys u c ha sm y e -
loma, growing basic studies and clinical trials reveal that
bortezomib can be used to treat many types of solid
tumors alone and in combination with other chemother-
apeutic drugs. This includes colon-gastric cancer [1-3],
breast cancer [4-9], prostate cancer [10-14] and lung
cancer [15-18] as well as others. Therefore, use of solid
tumor-derived cancer cell lines to study the mechanism
of bortezomib drug resistance is important for effective
application of bortezomib in treatment of patients with
solid tumors in the clinic.
Survivin, a unique member of the Inhibitor of Apop-
tosis (IAP) Protein Family, is cell cycle-regulated
[19,20] and its expression in cancer has been asso-
ciated with cancer progression, drug resistance, and
shortened patient survival [21,22]. Given that survivin
is highly expressed in malignant cells but is undetect-
able in most normal adult tissues, it is considered as a
potentially important therapeutic target [23]. Survivin
antagonizes apoptosis and is involved in the mitotic
spindle assembly checkpoint [24,25]. Thus, inhibition
of survivin expression or function induces both apop-
tosis and cell division defect. Many protein factors and
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expression of survivin [26]. For example, it has been
reported that p53 transcriptionally downregulates the
expression of survivin in various cancer cells with wild
type p53 [27-29], and the inhibition of survivin by p53
can be reversed by growth-stimulatory factors such as
estrogen receptor-a [30].
While survivin is a known universal drug resistant fac-
tor, the role and expression for survivin in bortezomib-
induced cancer cell growth inhibition and apoptosis
induction remains unclear. Some of the previous reports
noted that treatment of cancer cells with bortezomib is
associated with enhanced apoptosis and reduced expres-
sion of survivin [31,32], while other investigators
reported that bortezomib-induced apoptosis is accompa-
nied with an induction of survivin expression in human
NSCLC cells [33]. Recently, it has been also reported
that the role for survivin in bortezomib-induced apopto-
sis is cell type-dependent [34]. In this study, we demon-
strated that modulation of survivin expression by
bortezomib is dependent on p53 status but independent
of cancer cell type. In cancer cells with mutated p53 or
p53 null, bortezomib appears to induce survivin expres-
sion, while in cancer cells with wild type p53, bortezo-
mib either downregulates or shows no significant effect
on survivin, which is dependent on cell line, bortezomib
concentration and duration of exposure. These findings,
for the first time, unified the current different observa-
tions about the effect of bortezomib on survivin expres-
sion, apoptosis induction and bortezomib resistance, and
warranted further mechanistic studies and application of
these findings in cancer therapeutics.
Methods
Cell culture and reagents
Colon cancer cell lines (HCT116p53
+/+, HCT116p53
-/-),
lung cancer cell lines (EKVX and A549), prostate cancer
cells (PC-3 and LNCaP) and multiple myeloma cell lines
(KMS11 and RPMI8226) were maintained in RPMI 1640
medium. Breast cancer cells (MDA-MB-231 and MCF-
7) were cultured in DMEM medium. All cell cultural
mediums were supplied with 10% fetal bovine serum
(FBS, Atlanta Biologicals, Lawrenceville, GA) and peni-
cillin (100 units/ml)/streptomycin (0.1 μg/ml) (Invitro-
gen, Grand Island, NY). Cells were routinely
subcultured twice a week and maintained in a humidi-
fied incubator with 5% CO2 at 37°C. Polyclonal anti-
actin antibody and goat peroxidase-conjugated anti-rab-
bit IgG antibody were purchased from Sigma (St. Louis,
MO). Survivin antibody (FL-142) was purchased from
Santa Cruz (Santa Cruz, CA), MTT (tetrazolium salt, 3-
[4,5-dimethylthiazol-2-yl]-2,5,-diphenyltetrazolium bro-
mide) and leupeptin were purchased from Usb (Cleve-
land, OH).
Cell treatment and siRNA/shRNA transfection/infection
Cells grown in medium containing 10% serum were
treated with and without bortezomib in various concen-
trations (see text and results) for 24 - 72 hours were
harvested and followed by various analyses. siRNA
transfection [35] and shRNA infection [36] were per-
formed as previously described
MTT cell viability assay
Effect of bortezomib on cell growth was determined by
MTT assay. MTT was used as a colorimetric substrate
for measuring cell viability. Non-viable cells, with altered
cellular redox activity, are unable to reduce the MTT
dye. After 72 hours with or without bortezomib treat-
ment, MTT was added (to a final concentration of 0.5
mg/ml). Cells in 96-well plates were incubated in a 5%
CO2 incubator at 37°C for 4 hours, and then lysed thor-
oughly with lysis buffer (20% SDS, 50% N, N-dimethyl-
formamide, pH 4.7, 100 μl/well). The absorbance in the
relevant wells was measured at 570 nm using an Ultra
Microplate Reader (Bio-Tek Instruments).
Flow cytometry analysis
Cells at sub-confluence (~30%) were treated with borte-
zomib at 0, 5, 10 and 50 nM for 48 hours and then har-
vested by trypsinization and washed with PBS. Cells (~1
×1 0
6) were resuspended in 5 ml 70% ethanol. After the
initial fixation, cells were suspended in 0.5 ml PBS con-
taining 25 μg/ml propidium iodide (PI), 0.2% Triton X-
100 and 40 μg/ml RNase A and incubated for at least
30 minutes at 4°C. Cells were then analyzed for DNA
content profile by flow cytometry (FACScan, Becton
Dickinson, San Jose, CA) from 10,000 events per sample.
Data from flow cytometry were analyzed using WinList
software (Verity Software House Inc., Topsham, ME)
and presented as DNA content profiles (X axle) over
cell numbers (y axle). Triplicate assays were performed.
Western blot analysis
Cells with and without bortezomib treatment were
washed with phosphate-buffered saline (PBS) and lysed
on ice for 30 minutes in PBS containing 1% Nonidet P-
40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sul-
fate (SDS), 10 μg/ml phenylmethyl sulfonyl fluoride, and
20 μM leupeptin. Cell lysates were then centrifuged at
15,000 g for 20 minutes at 4°C. Fifty μg total proteins
from each sample were heated at 95°C for 5 minutes
after mixing with equal volume of 2 × SDS loading buf-
fer. Samples were separated on 12 - 15% SDS-polyacry-
lamide gel electrophoresis (SDS-PAGE) gels and
electrotransferred to Pure Nitrocellulose Membranes
(Bio-Rad, Hercules, CA). The membrane was then
blocked in 5% skim milk in TBS-T buffer (20 mM Tris/
HCl (pH 7.5), 0.137 M NaCl, and 0.05% Tween 20) at
room temperature for 2-3 hours; followed by incubation
of the membrane with primary antibodies (against survi-
vin or actin) in TBS-T containing 5% BSA overnight at
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After washing with TBS-T, the membrane was incu-
bated in TBS-T buffer containing 5% skim milk contain-
ing the corresponding secondary antibody (1:5000) for
45-60 minutes at room temperature with shaking. Pro-
tein of interest was detected using ECL (Perkin Elmer,
Waltham, MA) and visualized by autoradiography with
various times (5-60 seconds) of exposure. Actin was
detected as the internal control for normalization of
total protein loading in each lane.
Cell death detection ELISA assay
This assay is based on cell DNA fragmentation and the
cell death/DNA fragmentation was detected using the
Cell Death Detection ELISA
Plus assay kit (Roche) as
described previously [37]. Briefly, transfected
HCT116p53-/- cells were seeded in triplicates in 96-well
plates and treated with and without bortezomib for 48
hours. After removing medium, cells were then lysed
and 20 μl of lysate supernatant from each well were dis-
pensed into streptavidin-coated well-removable 96-well
plates followed by addition of 80 μl of immuno-reagents.
After a 2-hour incubation at room temperature,
unbound components were removed by washing with
1× incubation buffer for 3 times, followed by adding 100
μl of HRP substrate to each well, and the plate was
placed on a shaker at 250 rpm for color development.
Measurements were made at 405 nm against an ABTS
solution as a blank control using a microplate reader.
The absorbance value at 405 nm represents the quanti-
ties of DNA fragments/apoptosis induced by the
treatment.
Statistical analysis
A t-test was performed for a pair-wise comparison of
each experimental pair group with the control assum-
ing equal variance. The significance (p-value marked
with an asterisk “*”)w a ss e ta te q u a lt oo rl e s st h a n
0.05.
Results
Bortezomib-induced growth inhibition in HCT116 colon
cancer cells is dependent on p53 statuses
It was found that wild type p53 transcriptionally inhibits
survivin expression [27-29]. We reasoned that if survivin
plays a role in bortezomib resistance, p53 status might
affect bortezomib sensitivity to inhibit cancer cell
growth. Consistent with our rationale, p53 null HCT116
cells (HCT116p53
-/-) were resistant to bortezomib-
induced cell growth inhibition in comparison with
HCT116 with wild type p53 (Fig 1). This suggests a role
for the p53 status in bortezomib-induced cancer cell
growth inhibition, however it is not known whether the
difference of p53 status can also affect bortezomib-
induced cell death.
HCT116p53
-/- colon cancer cells are much more resistant
to bortezomib-mediated cell death in comparison with
wild type HCT116 cells
We then tested the effect of bortezomib on the induc-
tion of HCT116 colon cancer cell death with different
p53 status. Flow cytometry was used to determine DNA
content profiles as a parameter to evaluate cell death
after bortezomib treatment. This experiment revealed
that bortezomib treatment for 24 hours at 10 and 50
nM significantly induced sub-G1 DNA (representing
Figure 1 Colon cancer cell growth inhibition by bortezomib.
HCT116 colon cancer cells with p53 wild type (p53
+/+) and p53 null
(HCT116p53
-/-) were treated with bortezomib at different
concentrations for 48 hours. Cell growth was determined by MTT
assay (A) or by direct cell counting (B). The resultant data were
plotted in histogram by setting no bortezomib treatment controls
as OD values at 1 (A) or as cell numbers at 100. Each bar represents
the mean ± SD derived from three independent determinations.
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+/+ cells,
while this treatment showed minimal effect on
HCT116p53
-/- cells (Fig. 2). These observations (Figs 1
and 2) prompted us to investigate the potential role for
survivin in bortezomib resistance.




We reasoned that if survivin plays a role in bortezomib
resistance, survivin expression would be lower in
HCT116p53
+/+ cells than in HCT116p53-/- cells. Alter-
natively, bortezomib may decrease survivin expression in
HCT116p53
+/+ cells or increase survivin expression in
HCT116p53
-/- cells. To test the former possibility, survi-
vin expression was determined by western blots in both
HCT116p53
+/+ cells and HCT116p53
-/- cells. The result
indicated that the expression of survivin in HCT116p53
+/+ c e l l si sm u c hl o w e rt h a ni nH C T 1 1 6 p 5 3
-/- cells (Fig.
3A), suggesting the high expression of survivin in
HCT116p53
-/- cells may act as a contributing factor to
bortezomib resistance. Similar results were obtained in
other cancer cell lines with different p53 status (Fig.
3B). Consistently, MDA-MB-231 has much higher
tumorigenic ability than MCF-7 in mouse xenograft
models.
Bortezomib induces survivin expression in HCT116p53
-/-
cells but shows no significant effect on survivin
expression in HCT116p53
+/+ cells
We then tested whether bortezomib could differentially
modulate survivin expression between HCT116p53
+/+
cells and HCT116p53
-/- cells. Consistent with the fact
that HCT116p53
-/- cells are resistant to bortezomib-
induced growth inhibition and apoptosis induction, bor-
tezomib appears to significantly induce survivin expres-
sion in HCT116p53
-/- cells, while it shows minimal
i n d u c t i o no fs u r v i v i ni nH C T 1 1 6 p 5 3
+/+ cells (Fig. 4A).
Similar results were also obtained in other cancer cell
lines (Fig. 4B), indicating a general principle of this
phenomenon.
Figure 2 Colon cancer cell death induced by bortezomib. Sub-confluent HCT116 and HCT116p53
-/- cells were treated with and without
bortezomib at different concentrations as shown for 24 hours. Cells were then collected and stained with PI, followed by flow cytometry
analysis of DNA content profiles. A. The flow cytometry resultant data in histogram showed the striking difference in DNA content profiles
between HCT116 cells and HCT116p53
-/- cells. B. Histogram to compare the different percentage of cells in sub-G1 (dead cells) between HCT116
cells and HCT116p53
-/- cells. The histogram in B is the mean ± SD derived from two independent determinations.
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-/- cells by
survivin mRNA-specific siRNA sensitizes bortezomib-
induced growth inhibition
To test whether survivin expression indeed plays a role
in bortezomib resistance, we employed survivin mRNA-
specific siRNA approach [35] to silence survivin expres-
sion in HCT116p53
-/- cells, which highly expresses sur-
vivin. Significantly, we noted that silencing of the
expression of survivin (Fig. 5A) reverses bortezomib
resistance to growth inhibition (Fig. 5B) and cell death
induction (Fig. 5C) in HCT116p53-/- cells, while control
siRNA only showed a background effects similar to
those without transfection (not shown). Similarly, silen-
cing of survivin expression in MDA-MB-231 (p53 mut)
and PC-3 (p53 null) cells activates caspase-3 (Fig. 6), a
hallmark of apoptosis. These studies provide direct evi-
dence for the involvement of survivin expression in bor-
tezomib resistance.
Cancer cell sensitivity to bortezomib treatment is
dependent on p53 status but not cancer cell types
Previous studies indicated that modulation of survivin
expression by bortezomib, and cancer cell sensitivity to
bortezomib-induced apoptosis are cell type-dependent
[34]. Based on the data provided above, we hypothesized
that the different sensitivity to bortezomib for cancer
cells is due to p53 status-associated differential survivin
expression, and induction by bortezomib, rather than
cancer cell type. Here, we tested four pairs of cancer
cell lines with different p53 status from lung cancer
(EKVX with mutant p53 versus A549 with wild type
p53), breast cancer (MDA-MB-231 with mutant p53
versus MCF-7 with wild type p53), prostate cancer (PC-
3 with null p53 versus LNCaP with wild type p53) and
myeloma (RPMI-8226 with mutant p53 versus Kms11
with wild type p53). Consistent with our early data and
our rationale, bortezomib-mediated inhibition of cell
growth is significantly better in cancer cell lines with
wild type p53 in comparison to those cell lines with a
p53 null or p53 mutant status (Fig. 7), which is consis-
tent with the relative expression level of survivin in
these cells (Fig. 3A and 3B).
Discussion
Bortezomib is the first in class, proteasome inhibitor
that has demonstrated significant anticancer activity in
patients with lymphoid malignancies especially multiple
myeloma [38,39]. However, growing studies indicated
the potential effectiveness of bortezomib in treatment of
patients with solid tumor including colon-gastric cancer
[1-3], breast cancer [4-9], prostate cancer [10-14] and
lung cancer [15-18]. However, despite its impressive sin-
gle agent clinical activity in patients with either hemato-
poietic or solid malignancy, most patients either fail to
respond or develop resistance to bortezomib treatment.
Therefore, resistance to bortezomib is a challenging pro-
blem in the clinic. Identifying mechanism of bortezomib
resistance not only can help identify novel therapeutic
targets but will also contribute to better utilization of
this important therapeutic agent.
In the present study, we focus on the role of survivin
and p53 in bortezomib effectiveness as well as their
functional relationship in solid tumor cell lines. We
found that cancer cells with wild type p53 express much
less survivin in comparison with cancer cells with either
mutant or null p53. Moreover, bortezomib significantly
increased survivin expression in the HCT116 colon or
other cancer cell lines with p53 null, while it only
showed a minimal effect on survivin expression in
Figure 3 Survivin Expression in wild type vs. p53 null cancer
cell sublines. A. HCT116 and HCT116p53-/-. B. MCF-7 with wild
type p53 and MDA-MB-231 with mutant p53. C. Kms11 with wild
type p53 and RPMI-8226 with mutant p53. Sub-confluent cells were
lysed, and the cell lysates were used to determine survivin
expression by western blots. Actin is the internal control for total
protein loading. The expression of survivin in wild type p53 cells
was set at 1 and relative survivin expression is shown after
normalization with the actin internal control.
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-/- cells versus HCT116 cells. A. HCT116 and HCT116p53-/-. B. LNCap
with wild type p53 and PC-3 with null p53. Sub-confluent cells were treated with and without bortezomib for 48 hours. Cells were then
collected and lysed for western blots to determine survivin expression. Actin was used as the internal control for total lysate protein loading. The
expression of survivin in wild type p53 cells was set at 1 and relative survivin expression is shown after normalization with actin.
Figure 5 Effects of silencing of survivin expression on bortezomib sensitivity in HCT116p53-/- cells. The highly survivin expressing
HCT116p53-/- cells at 50% confluence were transfected with survivin mRNA-specific siRNAs or with control siRNAs. After 16 hours post
transfection, cells were treated with and without bortezomib for 48 hours. A part of the transfected cells were then collected for western blots
to determine survivin expression (A), a part of the transfected cells was used to determine cell growth inhibition by MTT assay (B), and the other
part of the transfected cells was used to determine cell death/DNA fragmentation by cell death ELISA assay (C). Data shown in B and C are the
mean ± SD derived from three independent determinations. Note: Results from cells without transfection were similar to cells transfected with
control siRNA/shRNA (not shown). The expression of survivin in HCT116p53-/- cells was set at 10 and relative survivin expression levels are
shown after normalized to actin.
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Consistent with these findings, while bortezomib effec-
tively inhibited cell growth and induced cell death in
cancer cells with wild type p53, bortezomib showed
ineffectiveness to inhibit cell growth and induce cell
death for the cancer cells with abnormal p53 (null or
mutated). We recognized that our experiment in Fig. 7
will be more convincing, if pairs of cancer cell lines as
we have for the HCT116 line (HCT116p53
+/+ vs.
HCT116p53
-/-) could be available to us for these experi-
ment. Nevertheless, the role of survivin in bortezomib
resistance was directly demonstrated in the study by
silencing of survivin in several cancer cell lines with
mutant p53 using survivin mRNA-specific siRNA/
shRNA technology previously set up in our laboratory
[35,36]. Finally, our investigations in three different pair
of cancer cell lines (originating from breast, lung and
prostate) with different p53 status demonstrated that
the p53 status-associated survivin expression is an
essential parameter to predict bortezomib resistance
irrespective of the origin of the cancer cell. Cancer cells
having a wild type p53 were sensitive while those with
abnormal p53 (mutated or null) were resistant to borte-
z o m i bt r e a t m e n t .C o n s i s t e n t with these findings, pre-
vious studies found that wild type p53 transcriptionally
inhibits survivin expression in various cancer cell types
[27-29] and bortezomib can stabilize wild type p53 in
prostate cancer cells [40]. Here, we would like to point
out that the bortezomib concentration used affects the
results, suggesting the dose used in the clinic should be
carefully considered. When high dose may kill cancer
cells better in a short term, high dose will increase the
possibility to generate bortezomib resistance, suggesting
that in addition to p53 status-associated survivin expres-
sion, other factors, such as other protein members in
the IAP and Bcl-2 families may also play important
roles in bortezomib resistance. Nevertheless, we have
confirmed a role for survivin in bortezomib resistance
by direct silencing of survivin expression using survivin-
specific siRNA/shRNA. This finding is significant
because our recent studies indicated that survivin may
be a superior cancer stem cell marker and possibly plays
critical role in cancer stem cell expansion [41]. In this
regard, cancer cells appear to have a higher percentage
of subpopulation cells that are tumorigenic (cancer initi-
ating/cancer stem cells) in xenograft mouse models [42].
Therefore, consideration of both survivin expression
and p53 status as interconnecting biomarkers and tar-
gets in cancer cells may not only be useful for predicting
the outcome of bortezomib treatment, but may also pro-
vide pivotal criteria for rational drug combination. For
example, bortezomib likely induces survivin expression
in cancer cells with mutated or null p53 (this study),
and it is known that paclitaxel rapidly induces survivin
expression [43]. Thus, combination of bortezomib and
paclitaxel likely obtained no good results in many cancer
types with such as the mutated p53 background.
Accordingly, a recent Phase II study in patients with
metastatic esophageal, gastric, and gastroesophageal can-
cer showed poor results in the drug combination [44].
However, it is also possible that the poor results derived
from such a drug combination involve other mechan-
isms of drug resistance in these tumors that are notor-
iously difficult to treat with chemotherapy.
An important question that needs be answered for
better application of the findings is the mechanism
underlying bortezomib-mediated induction of survivin
expression in mutated or null p53 cancer cells, while it
showed downregulation of or minimal effect on survivin
expression in wild type p53 cancer cells. Although
answering this critical question will need further
research efforts, based on the current available informa-
tion, the potential p53 and NF-B functional crosstalk
could provide a plausible explanation, although need to
Figure 6 Effects of silencing of survivin expression on
bortezomib sensitivity in other cancer cell with mutant p53.
Cell treatment condition is the same as in Figure 5. Cells were then
collected for western blots to determine survivin expression and/or
caspase-3 activation. A, MDA-MB-231 breast cancer cells are with
mutant p53. B, PC-3 prostate cancer cells are with p53 null.
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gene is a potential downstream target for p53 and NF-
B transcriptional regulation [26]. Alternatively, the pre-
vious finding that bortezomib stabilizes active form of
p53 in human LNCaP-Pro5 prostate cancer cells may
provide another explanation [40]. Nevertheless, while
survivin expression is inhibited by wild type p53 [27-29],
survivin and NF-B appear to be co-expressed in cancer
such as in peripheral T-cell lymphoma [45], and inhibi-
tion of NF-B activity using NF-B-specific inhibitors
decreased survivin expression [46]. Consistent with
these observations, bortezomib resistance requires NF-
B activity in mantle cell lymphoma [47]. Therefore, the
potential connection of these factors provide an interest-
ing underlying mechanism, which is likely similar to the
mechanism we recently discovered for the p53 and ERa
on the survivin gene control in the breast cancer [30].
Finally, the p53 status in RPMI-8226 and Kms11 is
not fully consistent in literature. Our literature search
indicates that RPMI-8226 has mutant p53 [48], while
Kms11 has wild type p53[49]. However, some publica-
tion indicated that Kms11 is p53 null. This is likely due
to the hypermethylation of the p53 gene to make p53
expression extremely low [50]. Consistently, our results
(Li and Chanan-Khan, unpublished observation) indi-
cated that the expression of p53 in Kms11 was barely
detected. Consistent with this, we found that the expres-
sion of survivin in Kms11 is comparable with its level in
RPMI-8226 (Fig. 3C).
Conclusion
In conclusion, based on the finding in this study, survi-
vin appears to play a role in bortezomib resistance. The
p53 status-associated survivin expression is an important
Figure 7 p53 status but not cancer cell type is a critical indicator for bortezomib sensitivity. Lung cancer cell lines (A, EKVX with mutant
p53 and A549 with wild type p53), breast cancer cell lines (B, MDA-MB-231 with mutant p53 and MCF-7 with wild type p53), prostate cancer
cell lines (C, PC-3 with null p53 and LNCaP with wild type p53) and myeloma cancer cell lines (D, RPMI-8226 with mutant p53 and KMS11 with
wild type p53) were seeded in 96-well cell cultural plates at 30% confluence. Cells were treated with and without a series of bortezomib
concentrations for 48 hours 16 hours after seeding. Cell growth/survival was then determined by MTT assay. The resultant data were represented
in histograms. Each bar is the mean ± SD derived from three independent determinations.
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largely independent of cancer cell types. Therefore, the
finding in this paper should be useful for not only pre-
diction of bortezomib sensitivity, but may also be useful
as an essential criterion for bortezomib combination
with other anticancer compounds for treatment of can-
cer patients.
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